Masculinity-Informed Therapeutic Discussions: Strengthening Father Engagement and Family Mental Health Systems - Psychiatry Online

(Toronto, October 16, 2026) — JMIR Publications this week released three News and Perspectives features on the latest digital health news: stories on how informed consent must be rethought for clinical trials involving AI; Canada’s proposed Safe Social Media Act and the Canadian Medical Association’s support; and a promising new autonomous oxygen titration device for health care. Designing Informed Consent for AI TrialsIn "Informed Consent in the AI Age: Why and How Documentation Must Change", JMIR Correspondent and researcher Hankun Su argues that traditional informed consent frameworks, which tend to assume that risks to patient safety are static and that clinicians will be able to fill in any gaps in understanding, are inadequate for clinical trials that use AI. “Documents must anticipate questions clinicians cannot answer and provide accessible responses within the text itself,” he writes. Su and his colleagues developed an informed consent framework for AI-related clinical trials that mandates transparency and disclosure, uses tiered standards based on risk, and employs dynamic consent mechanisms—one of many possible frameworks.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.